Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 7/20 | 0.63 |
| ▸ | RAD52 | P43351 | 5/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.63 |
| ▸ | GLA | P06280 | 4/20 | 0.63 |
| ▸ | GAA | P10253 | 4/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | MITF | O75030 | 2/20 | 0.63 |
| ▸ | TTR | P02766 | 1/20 | 0.63 |
| ▸ | TOP2A | P11388 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.51 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7880366 | 0.84 | POLB (0.78) | POLBRAD52KDM4EGLAGAA | |
| SCHEMBL3360006 | 0.80 | POLB (0.67) | POLBRAD52KDM4EGLAGAA | |
| SCHEMBL14740610 | 0.79 | POLB (0.61) | POLBRAD52KDM4EGLAGAA | |
| Trifluoroacetic Acid SCHEMBL8273518 | 0.78 | KDM4E (0.48) | POLBRAD52KDM4EGLAGAA | |
| SCHEMBL15867898 | 0.78 | POLB (0.59) | POLBRAD52KDM4EGLAGAA | |
| Trifluoroacetic Acid SCHEMBL7875800 | 0.78 | GSR (0.72) | KDM4EKMT2AMEN1 | |
| SCHEMBL17154415 | 0.78 | POLB (1.00) | POLBRAD52KDM4EGLAGAA | |
| SCHEMBL7869214 | 0.77 | POLB (0.79) | POLBRAD52KDM4EGLAGAA | |
| SCHEMBL5578493 | 0.77 | POLB (0.79) | POLBRAD52KDM4EGLAGAA | |
| SCHEMBL15867118 | 0.76 | POLB (0.67) | POLBRAD52KDM4EGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031763-A1 | Substituted bis-acridines and related compounds as CCR5 receptor ligands, anti-inflammatory agents and anti-viral agents | SMITHKLINE BEECHAM CORPORATION | 2001-10-18 | — | — | US | claimed |
| EP-0979078-A4 | SUBSTITUTED BIS-ACRIDINES AND RELATED COMPOUNDS AS CCR5 RECEPTOR LIGANDS, ANTI-INFLAMMATORY AGENTS AND ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORP (US) | 2000-06-21 | — | — | EP | claimed |
| EP-0979078-A1 | SUBSTITUTED BIS-ACRIDINES AND RELATED COMPOUNDS AS CCR5 RECEPTOR LIGANDS, ANTI-INFLAMMATORY AGENTS AND ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-16 | — | — | EP | claimed |
| WO-1998030218-A1 | SUBSTITUTED BIS-ACRIDINES AND RELATED COMPOUNDS AS CCR5 RECEPTOR LIGANDS, ANTI-INFLAMMATORY AGENTS AND ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-16 | — | — | WO | claimed |
| EP-4143235-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | IncellDx, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222069-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | INCELLDX, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-20010031763-A1 | Substituted bis-acridines and related compounds as CCR5 receptor ligands, anti-inflammatory agents and anti-viral agents | SMITHKLINE BEECHAM CORPORATION | 2001-10-18 | — | — | US | disclosed |
| US-6242459-B1 | Substituted bis-acridines and related compounds as CCR5 receptor ligands, anti-inflammatory agents and anti-viral agents | SMITHKLINE BEECHAM CORPORATION | 2001-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031763-A1 | Substituted bis-acridines and related compounds as CCR5 receptor ligands, anti-inflammatory agents and anti-viral agents | CCR5, CCR2, CCR1 | POLB 2481/4885RAD52 3064/4885KDM4E 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.